CD274 and cancer: Immune checkpoint inhibitors (ICIs), which are represented by programmed cell death (ligand) 1 (PD‐1/PD‐L1) inhibitors or cytotoxic T lymphocyte antigen 4 (CTLA‐4) inhibitors, have achieved remarkable success across multiple types of cancers.1, 2, 3, 4, 5